Biogen executive Samantha Budd Haeberlein leaves company
Biogen's Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
The news comes just two weeks after the FDA's Billy Dunn, who worked closely with Budd Haeberlein on Aduhelm’s path to approval, abruptly left the agency. Between 2019 and 2021, when Aduhelm was approved, the two worked closely together in a process “rife with irregularities,” according to a subsequent congressional report.
“We wish her the best in her future endeavors,” a Biogen spokesperson told STAT.
Biogen's Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
The news comes just two weeks after the FDA's Billy Dunn, who worked closely with Budd Haeberlein on Aduhelm’s path to approval, abruptly left the agency. Between 2019 and 2021, when Aduhelm was approved, the two worked closely together in a process “rife with irregularities,” according to a subsequent congressional report.
“We wish her the best in her future endeavors,” a Biogen spokesperson told STAT.